- Home
- ELDN vs VTYX Comparison
ELDN vs VTYX Comparison
Compare ELDN & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELDN
- VTYX
- Stock Information
- Founded
- ELDN 2004
- VTYX 2018
- Country
- ELDN United States
- VTYX United States
- Employees
- ELDN N/A
- VTYX N/A
- Industry
- ELDN Biotechnology: Pharmaceutical Preparations
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- ELDN Health Care
- VTYX Health Care
- Exchange
- ELDN Nasdaq
- VTYX Nasdaq
- Market Cap
- ELDN 140.3M
- VTYX 148.4M
- IPO Year
- ELDN N/A
- VTYX 2021
- Fundamental
- Price
- ELDN $4.07
- VTYX $1.73
- Analyst Decision
- ELDN Strong Buy
- VTYX Buy
- Analyst Count
- ELDN 1
- VTYX 5
- Target Price
- ELDN $16.00
- VTYX $8.40
- AVG Volume (30 Days)
- ELDN 1.0M
- VTYX 1.1M
- Earning Date
- ELDN 11-12-2024
- VTYX 11-07-2024
- Dividend Yield
- ELDN N/A
- VTYX N/A
- EPS Growth
- ELDN N/A
- VTYX N/A
- EPS
- ELDN N/A
- VTYX N/A
- Revenue
- ELDN N/A
- VTYX N/A
- Revenue This Year
- ELDN N/A
- VTYX N/A
- Revenue Next Year
- ELDN N/A
- VTYX N/A
- P/E Ratio
- ELDN N/A
- VTYX N/A
- Revenue Growth
- ELDN N/A
- VTYX N/A
- 52 Week Low
- ELDN $1.11
- VTYX $1.67
- 52 Week High
- ELDN $5.54
- VTYX $11.48
- Technical
- Relative Strength Index (RSI)
- ELDN 51.95
- VTYX 30.10
- Support Level
- ELDN $3.76
- VTYX $2.10
- Resistance Level
- ELDN $4.17
- VTYX $2.36
- Average True Range (ATR)
- ELDN 0.39
- VTYX 0.12
- MACD
- ELDN -0.15
- VTYX -0.05
- Stochastic Oscillator
- ELDN 18.45
- VTYX 8.76
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.